ASCO in ActionASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.

To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.

Tune in to ASCO's new ASCO in Action podcast series, providing analysis and commentary on cancer policy and practice issues, available through iTunes or Google Play.

November 14, 2019

From the American Society of Clinical Oncology in cooperation with the Food and Drug Administration (FDA) and as a service to our members, ASCO will periodically distribute information about newly approved therapies for cancer patients. This helps FDA inform oncologists and professionals in oncology-related fields about recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety.

November 14, 2019

CancerLinQ LLC, a nonprofit subsidiary of ASCO, and the American Heart Association, the leading voluntary health organization devoted to a world of longer, healthier lives, are teaming up to make oncology datasets from the CancerLinQ Discovery® database available to academic researchers, non-profits, health care providers and government agencies through a customized version of the American Heart Association’s Precision Medicine Platform.

November 13, 2019

The MEDS Act takes important steps toward ending the drug shortage crisis we are experiencing today, ASCO Board of Directors member Peter C. Adamson, MD stated during a briefing on Capitol Hill. Dr. Adamson spoke in support of Senate bill S. 2723, “The Mitigating Emergency Drug Shortages (MEDS) Act,” at the November 5 briefing.

November 12, 2019

Norman “Ned” Sharpless, MD, returned to his post of Director of the National Cancer Institute (NCI) earlier this month. Dr. Sharpless had been serving as Acting Commissioner of the Food and Drug Administration (FDA) since Dr. Scott Gottlieb stepped down in April 2019.

Earlier this month, President Trump announced his nomination of Dr. Stephen Hahn to serve as the new Commissioner of the FDA. Admiral Brett Giroir, MD, will serve as Acting Commissioner of the FDA until a permanent commissioner is confirmed by the Senate.

November 12, 2019

The U.S. Food and Drug Administration (FDA) recently announced a reorganization and renaming of the office responsible for reviewing applications for new and existing cancer therapies.

The Center for Drug Evaluation and Research (CDER) Office of Hematology and Oncology Products (OHOP) has been renamed the Office of Oncologic Diseases (OOD). Richard Pazdur, MD, will serve as the acting director of OOD and continue his role as director of the FDA Oncology Center of Excellence (OCE).

November 8, 2019
From the American Society of Clinical Oncology in cooperation with the Food and Drug Administration (FDA) and as a service to our members, ASCO will periodically distribute information about newly approved therapies for cancer patients. This helps FDA inform oncologists and professionals in oncology-related fields about recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety.
November 7, 2019

Twenty-Four practices in two countries elevated their standard of care and achieved ASCO's  Quality Oncology Practice Initiative (QOPI®) Certification in the third quarter of this year. 

November 6, 2019

Medical oncologists in Brazil are being encouraged to take advantage of a new measure set for assessing the quality of care they provide to patients with lung cancer through a collaboration between ASCO and the International Association for the Study of Lung Cancer (IASLC).

November 1, 2019

On November 1, the Centers for Medicare & Medicaid Services (CMS) released its final rule for reimbursement under the Hospital Outpatient Prospective Payment System (HOPPS) in 2020. ASCO is still analyzing the rule and will provide in-depth analysis for members as soon as possible. Based on a preliminary evaluation, key provisions in the proposed rule include:

November 1, 2019

On November 1, the Centers for Medicare & Medicaid Services (CMS) released its final rule for the 2020 Medicare Physician Fee Schedule (MPFS) and other changes to Medicare Part B reimbursement policies, including proposals related to the Quality Payment Program (QPP).

November 1, 2019

“The American Society of Clinical Oncology (ASCO) congratulates Stephen M. Hahn, MD, FASTRO, on his nomination by President Trump to serve as the next Commissioner of the Food and Drug Administration (FDA). An oncologist and long-time member of ASCO, Dr. Hahn currently serves as the Chief Medical Executive at The University of Texas MD Anderson Cancer Center. He has a strong grasp of the drug development process and understands the realities of working in a complex clinical care environment at one of the largest cancer centers in the world. 

October 30, 2019

ASCO developed a Decision Aid to assist physician-investigators and research staff in determining whether an AE should be reported to the sponsor as an SAE and attributed to the investigational drug.

October 30, 2019

In a letter to leaders of the U.S. Senate and House of Representatives, ASCO, along with more than 100 other medical groups, urged Congress to protect patients from unanticipated, or “surprise,” medical bills that can occur when gaps in health insurance coverage lead them to receive care from out-of-network providers.

October 30, 2019

Health insurers, employers, and pharmacy benefit managers (PBMs) have shifted a growing share of the costs for specialty prescription medicines to their patients and beneficiaries. Since insurer cost-sharing requirements for prescription medications (such as high coinsurance and deductible amounts) can be uniquely burdensome compared to other types of health care, pharmaceutical manufacturers regularly offer co-pay assistance—which can include co-pay cards or coupons—to help patients afford their prescriptions.

October 30, 2019

ASCO’s Government Relations Committee Chair-elect, Carolyn Hendricks, MD, FASCO, spoke at a congressional briefing organized by the One Voice Against Cancer coalition about the importance of federal funding in making progress against cancer. ASCO also recently urged the leaders of the House and Senate Appropriations Committees to quickly enact a FY 2020 funding bill that includes robust, sustained funding for the NIH.

Pages